What Has Been Tried and What Is True?

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

PRODIGY Objective Study Design Primary Composite Endpoint

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

NSTE Acute Coronary Syndromes

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

CHU TIMONE, Marseille, FR

_________________ Caitlin M. Gibson, PharmD, BCPS

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Stent Thrombosis and Optimal Duration of DAPT

Denise Sutter, PharmD, BCPS

Short versus Long DAPT Studies – An Academic View

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

European and US Guidelines

(p < for group 1 or 2 vs. group 3)

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

Achieving Long-Term Protection Post-MI

Emerging Data on ACS Management From ACC

Applying New Data in Practice:

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

PAD Patients vs Post-ACS Patients:

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Tailoring Antiplatelet Therapy in PCI

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

PCSK9 Inhibitors and Cardiovascular Outcomes

A Better Solution For Cancer Patients With VTE?

New LDL-C Lipid Targets

Extraordinary Cases of VTE Prevention in Patients With Cancer

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

CV Risk Doesn't End in the Cath Lab

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

Identifying High-Risk AF Patients

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Duration of Dual Antiplatelet Therapy

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Updates in Anticoagulation: Key Sessions at ESC 2017

What oral antiplatelet therapy would you choose?

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

DECLARE-TIMI 58.

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Primary safety endpoint

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

PCSK9 Inhibitors and Real-World Evidence

Antithrombotic Therapy in AF Patients Undergoing PCI

Translating Data From Trial to Practice

Presentation transcript:

What Has Been Tried and What Is True?

What Has Changed?

Less Stent Thrombosis With New-Generation DES

What Are the Results of the Randomized Trials on the Duration of DAPT After Stenting?

Shorter Duration of DAPT Trials

DAPT Study Primary Safety Endpoint: Moderate or Severe Bleeding 12 to 30 Months

PEGASUS-TIMI 54 Study Design

PEGASUS-TIMI 54: Estimates of First Efficacy and Bleeding Events "Prevented" and "Caused"

PEGASUS- TIMI 54: Reduction in MACE With Ticagrelor by Time From P2Y12 Inhibitor Withdrawal

Duration of DAPT Trials

What Are the Current Guidelines on the Duration of DAPT After Coronary Stenting?

2014 ESC/EACTS Guidelines on Myocardial Revascularization

2016 ACC/AHA Guideline Focused Update on Duration of DAPT in Patients With CAD

2016 ACC/AHA Guideline Focused Update on Duration of DAPT in Patients With CAD (cont)

DAPT Score

2016 ACC/AHA Guideline Focused Update on Duration of DAPT in Patients With CAD (cont)

Clinical Cases

Case 1

Case 2

Case 3

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)